Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate Positive Bioequivalence Data in Clinical Therapeutics
| UNCY Stock | USD 0.79 0.02 2.47% |
Slightly above 62% of Unicycive Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Unicycive Therapeutics stock suggests that many investors are alarmed at this time. Unicycive Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Unicycive Therapeutics' earnings reports, geopolitical events, and overall market trends.
Unicycive |
LOS ALTOS, Calif., Dec. 17, 2024 -- Unicycive Therapeutics, Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease , today announced that data from the Companys oxylanthanum carbonate bioequivalence study in healthy volunteers was published in the peer-reviewed journal, Clinical Therapeutics. The publication, entitled, Two-Way Randomized Crossover Study to Establish Pharmacodynamic B
Read at finance.yahoo.com
 |
Unicycive Therapeutics Fundamental Analysis
We analyze Unicycive Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Unicycive Therapeutics is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Unicycive Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Unicycive Therapeutics stock to make a market-neutral strategy. Peer analysis of Unicycive Therapeutics could also be used in its relative valuation, which is a method of valuing Unicycive Therapeutics by comparing valuation metrics with similar companies.
Peers
Unicycive Therapeutics Related Equities
| CDIO | Cardio Diagnostics | 12.20 | ||||
| RNAZ | Transcode Therapeutics | 10.37 |
Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.